Navigation Links
NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Date:5/28/2008

SOPHIA ANTIPOLIS, France, May 28 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have been randomized in 120 clinical centers in North America and Europe in this study, which is the final phase 3 trial in NicOx' clinical plan for the regulatory filing of naproxcinod. The objective of this study is to assess naproxcinod's efficacy in relieving the signs and symptoms of osteoarthritis of the hip and provide additional safety data, including further information on naproxcinod's blood pressure profile in comparison to another anti-inflammatory medication. Results from this study are expected in Q4 2008 and NicOx projects the filing of a New Drug Application (NDA) in mid-2009.

NicOx is currently in the final stages of developing naproxcinod as an investigational drug for treating the signs and symptoms of osteoarthritis. Naproxcinod is the most advanced compound in a novel class of anti-inflammatory agents known as the Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs). The 303 study follows the previous two pivotal phase 3 trials. Successful results were obtained in the 301 phase 3 study, in patients with osteoarthritis of the knee (see press release of October 27, 2006). These data demonstrated superior efficacy to placebo. Data collected suggested that naproxcinod could have no detrimental effect on blood pressure, in contrast to naproxen, a widely used non-steroidal anti-inflammatory drug (NSAID). NSAIDs are known to have the tendency to elevate blood pressure to an extent that may increase the rate of serious cardiovascular adverse events, such as heart attack and stroke.

The 302 study for naproxcinod in patients with osteoarthritis of the knee (see press release of April 3, 2007) is due to report results in Q3 2008.

Maarten Beekman, Vice
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
2. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
7. NicOx Naproxcinod ABPM Data Presented at American Heart Association
8. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
9. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
(Date:12/19/2014)... Since last month,s FBI shutdown of online drug marketplace ... online black market for illegal drugs - Evolution Marketplace ... drugs and other illegal items.  New numbers from the ... lowering the numbers of drugs and illegal items available ... But some new sites that have emerged as potentially ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the growth ... a later starter. In 2012, the size of ... with the proportion worldwide soaring to 16.3%. It is projected ... continue its growth rate by around 20% in the upcoming ... roughly RMB25 billion. An integrated membrane industrial system ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... announces that a new market research report ... Pharmaceutical Manufacturers - Global ... register contains information about 8092 manufacturers of ... the following details of the manufacturers: ...
... Simon Orobor, owner of Power Wheelchair Services, Inc., located ... truck and trailer rentals to the power wheelchair rental- ... since 2009. (Logo: http://photos.prnewswire.com/prnh/20090622/LA34860LOGO-b ) ... this press release. Families needing the ...
Cached Medicine Technology:Power Wheelchair Services, Inc. Assists Customers in More Ways Than One With U-Haul Products and Services 2Power Wheelchair Services, Inc. Assists Customers in More Ways Than One With U-Haul Products and Services 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... private practices that have made outstanding and innovative ... support and progression of private practice physical therapy ... Physical Therapy Association. , On behalf of Performance ... owner and CEO of Performance accepted the award ...
(Date:12/17/2014)... A group of 127 scientists sent an “open ... to a recent statement by the center that was highly ... the efficacy of all brain exercises. , Signatories to the ... the center’s statement critical of brain exercise companies that overstate ... its case, in a document it had entitled “A Consensus ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... phenomenon is when an illness that originated in animals jumps ... -- is not uncommon and keeps researchers on their toes ... make inroads into the human population. A new report ... in this case were guinea pigs. More specifically, they were ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3
... May 5 Today marks the launch of the ... network designed to focus exclusively on hospice and palliative ... their families worldwide need palliative care and support each ... cent actually receive it. The need for palliative care ...
... project entitled ,Good Practice in Traditional Chinese Medicine Research ... status of Traditional Chinese Medicine (TCM) research, identify problems ... as well as providing a forum for the exchange ... EU and China. , The three-year project ...
... Increase Hispanic Family Physicians in California LOS ANGELES and ... a $2 million grant to the David Geffen School ... , to expand its International Medical Graduate Program. The ... to serving California,s vulnerable communities and need to pass ...
... (NYSE: BSX ) is scheduled to participate ... Health Care Conference.Jim Tobin, President and Chief Executive Officer, ... beginning at approximately 9:20 a.m. E.T. Following the ... Officer will join Mr. Tobin in a question and ...
... With a Donation, TooNEW YORK, May 5 Honk if you,re ... their wheels trying to think of the perfect Mother,s Day gift, ... to make a unique gift -- one that may save lives ... You can use this traditional time of love and giving to ...
... wary of finding, however , , TUESDAY, May 5 (HealthDay ... the long-sought markers that could discern which tumors are ... , The currently hot debate about the value of ... the fact that the cancer is usually so slow-growing ...
Cached Medicine News:Health News:New International Alliance Launched to Address Urgent Needs of Palliative Care Patients Worldwide 2Health News:King's-led consortium wins €1 million EU funding for Chinese medicine research 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 3Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 4Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 2Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 3
For the quantitative determination of luteinizing hormone (LH) concentration in human serum....
... Luteinizing hormone (LH) is a glycoprotein ... the FSH, hCG and TSH, the intact ... alpha- and beta-subunits. These glycoproteins all have ... unique beta-subunit. Both LH and FSH production ...
Microwell-EIA for the detection of GAD Autoantibody....
... StreamLAB combines consolidated analytical ... with pre- and post-analytical ... innovative laboratory automation solution ... of today's laboratories, as ...
Medicine Products: